KYV-101 (mivocabtagene autoleucel)
Lupus Nephritis
Key Facts
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biotech company with a mission to liberate autoimmune patients through the curative potential of engineered cell therapies. Founded in 2018 and publicly listed in 2024, the company has rapidly advanced its clinical pipeline, having treated over 100 patients across multiple autoimmune indications. Its strategy centers on translating the proven success of CD19-targeting CAR T-cells from oncology to autoimmunity, aiming to achieve deep B-cell depletion, immune reset, and long-term, treatment-free remission.
View full company profileAbout Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biotech company with a mission to liberate autoimmune patients through the curative potential of engineered cell therapies. Founded in 2018 and publicly listed in 2024, the company has rapidly advanced its clinical pipeline, having treated over 100 patients across multiple autoimmune indications. Its strategy centers on translating the proven success of CD19-targeting CAR T-cells from oncology to autoimmunity, aiming to achieve deep B-cell depletion, immune reset, and long-term, treatment-free remission.
View full company profileAbout Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biotech company with a mission to liberate autoimmune patients through the curative potential of engineered cell therapies. Founded in 2018 and publicly listed in 2024, the company has rapidly advanced its clinical pipeline, having treated over 100 patients across multiple autoimmune indications. Its strategy centers on translating the proven success of CD19-targeting CAR T-cells from oncology to autoimmunity, aiming to achieve deep B-cell depletion, immune reset, and long-term, treatment-free remission.
View full company profileAbout Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biotech company with a mission to liberate autoimmune patients through the curative potential of engineered cell therapies. Founded in 2018 and publicly listed in 2024, the company has rapidly advanced its clinical pipeline, having treated over 100 patients across multiple autoimmune indications. Its strategy centers on translating the proven success of CD19-targeting CAR T-cells from oncology to autoimmunity, aiming to achieve deep B-cell depletion, immune reset, and long-term, treatment-free remission.
View full company profileAbout Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biotech company with a mission to liberate autoimmune patients through the curative potential of engineered cell therapies. Founded in 2018 and publicly listed in 2024, the company has rapidly advanced its clinical pipeline, having treated over 100 patients across multiple autoimmune indications. Its strategy centers on translating the proven success of CD19-targeting CAR T-cells from oncology to autoimmunity, aiming to achieve deep B-cell depletion, immune reset, and long-term, treatment-free remission.
View full company profileTherapeutic Areas
Other Lupus Nephritis Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 1/2 |
| Ramatroban (KAR101) | KARE Biosciences | Preclinical |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| LUPKYNIS (voclosporin) | Aurinia Pharmaceuticals | Approved |
| NKX019 | Nkarta | Phase 1 |
| Zetomipzomib (KZR-616) | Kezar Life Sciences | Phase 2 |